Merck Animal Health to Host Symposium on Emerging Diseases at 23rd International Pig Veterinary Society Congress
“Emerging Diseases: Learning from the Past to Prepare for the Future”
SUMMIT, NEW JERSEY, May 28, 2014 – Merck Animal Health (known as MSD Animal Health outside the USA and Canada) today announced it will host a symposium, “Emerging Diseases: Learning from the Past to Prepare for the Future,” during the 23rd International Pig Veterinary Society Congress in Cancun, Mexico. The symposium will be held on Tuesday, June 10 from 4:30 to 6:00 p.m. in Room G of the Moon Palace Arena.
“Diseases such as porcine reproductive and respiratory syndrome (PRRS) and porcine epidemic diarrhea (PED) are expanding to new geographical areas and imposing significant costs on pig producers,” said Narciso Bento, Global Swine Business, Merck Animal Health. “We are proud to partner with leading experts to offer this symposium at the 23rd International Pig Veterinary Society Congress, which will provide producers with important information to help them manage and prevent outbreaks.”
The symposium will feature four presentations from academics, industry leaders and Merck Animal Health experts on emerging diseases affecting swine. Audio translations of the presentations will be available in Spanish and Portuguese, and attendees will receive a free reference book in English or Spanish, “Handbook of Laboratory Diagnosis in Swine,” coordinated by Dr. Quim Segalés. Presentations at the symposium include:
- Emerging disease outbreaks: from PRRS to PED
Dr. Quim Segalés, Professor, University of Barcelona, CReSA, Barcelona, Spain
- Research and development for new emerging diseases
Dr. Erin Strait, Director, US-Swine Biologicals Research and Development, Merck Animal Health, DeSoto, Kansas, USA
- Experiences of a swine veterinarian in front of an emerging disease, what did we learn?
Dr. Matt Ackerman, Partner, Swine Veterinary Services, Greensburg, Indiana, USA
- Managing disease outbreaks: Creating and promoting health through batch systems
Dr. Miquel Collell, Global Technical Director Swine, Merck Animal Health, Summit, New Jersey, USA
For more information about the 23rd International Pig Veterinary Society Congress, visit http://www.ipvs2014.org.
About Merck Animal Health
Today’s Merck is a global healthcare leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com.
Merck forward-Looking Statement
This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2013 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).